– Top-tier investor syndicate led by Matrix Capital, with participation from the Global Health Investment Corporation, Cercano Management, The Washington Research Foundation, Boom Capital Ventures, Sahsen Ventures, and Pack Ventures. – Financing will be used to advance Monod’s technology platform and create de novo modular and tunable protein biosensors for rapid point-of-care medical diagnostics and … [Read more…]
CARLSBAD, Calif.–(BUSINESS WIRE)–$LCTX #LineageCellTherapeutics—Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today Brian M. Culley, Lineage’s Chief Executive Officer, will present at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference, in a fireside chat hosted by Joseph Pantginis, Ph.D., Director of … [Read more…]
Collaboration focuses on developing and implementing real-world research to drive patient access to cancer medicines CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING–(BUSINESS WIRE)–$BGNE #BTKi—BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company that is developing and commercializing innovative and affordable oncology medicines to improve treatment outcomes and access for far more patients worldwide, … [Read more…]
– Received FDA acceptance of BLA for omidubicel with Priority Review; PDUFA target action date set for January 30, 2023 – – Dosed first patient in company-sponsored Phase 1/2 study of cryopreserved formulation of GDA-201 for the treatment of follicular and diffuse large B-cell lymphomas – – Finished second quarter of 2022 with $55.1 million … [Read more…]
– Phase II acute pain program to initiate in September – Ended quarter with $50 million in cash and equivalents, providing over two years of runway TORONTO–(BUSINESS WIRE)–$ATBPF–Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, has filed its financial … [Read more…]
Plenity Q2 product revenue increased 312% year-over-year to $9.0 million Gross profit in Q2 increased by $4.0 million year-over-year, with gross margin improving to 47% from 8% BOSTON–(BUSINESS WIRE)–Gelesis (NYSE: GLS), the maker of Plenity for weight management, today reported financial results for the second quarter of 2022. “We are seeing both consumers and clinicians … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “Large Joint Devices Market Report Suite – Global – 2022-2028 – MedSuite” report has been added to ResearchAndMarkets.com’s offering. The total Global Large Joint Devices Market is growing at a rate of 4.8%, which will take the 2021 market value of $19 billion up to $26 billion by 2028. One of the top … [Read more…]
ForGround offers tools, resources, and discounts to advance the adoption of climate smart practices that can transform value chains Potential benefits from transitioning to regenerative agriculture may include improved soil health1, reduced water use2, fewer inputs3, increased weather resiliency4 and less soil erosion5 The platform has been built on Bayer’s years of experience and knowledge … [Read more…]
Results consistent with previous trials, reinforcing benefit of Daiichi Sankyo and AstraZeneca’s ENHERTU in previously treated patients TOKYO & MUNICH & BASKING RIDGE, N.J.–(BUSINESS WIRE)–Positive topline results from the DESTINY-Breast02 phase 3 trial of ENHERTU® (trastuzumab deruxtecan) versus physician’s choice of treatment showed the trial met the primary endpoint, demonstrating a statistically significant and clinically … [Read more…]
All claims made by Seagen regarding Daiichi Sankyo antibody drug conjugates are denied TOKYO & MUNICH & BASKING RIDGE, N.J.–(BUSINESS WIRE)–An arbitrator issued a decision today in a dispute between Daiichi Sankyo Company, Ltd. and Seagen, Inc., denying all claims made by Seagen. Specifically, Daiichi Sankyo retains all patent rights to its antibody drug conjugate … [Read more…]
